This is a first-in-human, 3-part study to investigate the safety, tolerability, and
effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents
in patients with locally advanced (unresectable) and/or metastatic human epidermal growth
factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the
body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).